MA28088A1 - Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci - Google Patents

Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci

Info

Publication number
MA28088A1
MA28088A1 MA28921A MA28921A MA28088A1 MA 28088 A1 MA28088 A1 MA 28088A1 MA 28921 A MA28921 A MA 28921A MA 28921 A MA28921 A MA 28921A MA 28088 A1 MA28088 A1 MA 28088A1
Authority
MA
Morocco
Prior art keywords
ser
val
thr
pro
leu
Prior art date
Application number
MA28921A
Other languages
English (en)
Inventor
Carmen Barske
Stefan Frentzel
Anis Khusro Mir
Martin E Schwab
Alessandra Vitaliti
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of MA28088A1 publication Critical patent/MA28088A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

130 135 140 Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gin Thr Asn Ser Met Val Thr 145 150 155 160 Leu Gly cys Leu Val Lys Gly Tyr Phe Pro Grd Pro Val Thr Val Thi 165 170 175 Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val 180 185 190 Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 195 200 205 Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala 210 215 220 <210> 3 <211> 238 <212> PRT <213> Mus musculus <220> <221> CHAIN
MA28921A 2003-09-19 2006-04-07 Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci MA28088A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321997.9A GB0321997D0 (en) 2003-09-19 2003-09-19 Organic compound

Publications (1)

Publication Number Publication Date
MA28088A1 true MA28088A1 (fr) 2006-08-01

Family

ID=29266310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28921A MA28088A1 (fr) 2003-09-19 2006-04-07 Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci

Country Status (25)

Country Link
US (2) US20090181023A1 (fr)
EP (3) EP2423225A3 (fr)
JP (1) JP2007527232A (fr)
KR (1) KR20060119982A (fr)
CN (1) CN1878792A (fr)
AR (1) AR045671A1 (fr)
AU (2) AU2004274164B2 (fr)
BR (1) BRPI0414174B8 (fr)
CA (1) CA2538725C (fr)
CO (1) CO5680457A2 (fr)
EC (1) ECSP066431A (fr)
GB (1) GB0321997D0 (fr)
IL (2) IL174145A (fr)
IS (1) IS8404A (fr)
MA (1) MA28088A1 (fr)
MY (2) MY161068A (fr)
NO (1) NO20061678L (fr)
NZ (1) NZ545679A (fr)
PE (1) PE20050949A1 (fr)
RU (1) RU2380377C2 (fr)
SG (1) SG146660A1 (fr)
TN (1) TNSN06085A1 (fr)
TW (1) TWI372060B (fr)
WO (1) WO2005028508A2 (fr)
ZA (1) ZA200601842B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
WO2006059959A1 (fr) * 2004-12-01 2006-06-08 National University Of Singapore Fragments proteiniques nogo-a utiles comme peptides ayant une interaction avec le reseau neuronal
HRP20120851T1 (hr) * 2005-07-05 2012-11-30 Glaxo Group Limited Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (fr) 2012-07-05 2015-05-08 Glaxo Group Ltd
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体
CN114470197B (zh) * 2022-02-16 2023-10-03 天津长和生物技术有限公司 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用
WO2024041450A1 (fr) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 Anticorps pour reconnaître de manière spécifique nogo-a et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0383417B1 (fr) 1989-02-13 1995-12-27 Schering Aktiengesellschaft Activateur du plasminogène salivaires de chauve-souris vPA-alpha 1
DE69942803D1 (de) * 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
AU2002357770B2 (en) * 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases

Also Published As

Publication number Publication date
NO20061678L (no) 2006-06-16
PE20050949A1 (es) 2005-12-16
US20110008334A1 (en) 2011-01-13
ZA200601842B (en) 2007-09-26
BRPI0414174B1 (pt) 2019-06-04
TNSN06085A1 (en) 2007-10-03
BRPI0414174A (pt) 2006-10-31
NZ545679A (en) 2009-11-27
BRPI0414174B8 (pt) 2021-05-25
MY158078A (en) 2016-08-30
RU2380377C2 (ru) 2010-01-27
JP2007527232A (ja) 2007-09-27
IS8404A (is) 2006-04-10
AU2009200237B2 (en) 2011-05-19
AU2004274164B2 (en) 2009-02-05
CA2538725C (fr) 2010-12-21
KR20060119982A (ko) 2006-11-24
WO2005028508A2 (fr) 2005-03-31
AR045671A1 (es) 2005-11-02
IL174145A0 (en) 2006-08-01
US20090181023A1 (en) 2009-07-16
WO2005028508A3 (fr) 2005-07-07
CA2538725A1 (fr) 2005-03-31
GB0321997D0 (en) 2003-10-22
MY161068A (en) 2017-04-14
SG146660A1 (en) 2008-10-30
AU2009200237A1 (en) 2009-02-12
AU2004274164A1 (en) 2005-03-31
ECSP066431A (es) 2006-09-18
IL174145A (en) 2010-11-30
EP2423225A2 (fr) 2012-02-29
TW200517123A (en) 2005-06-01
CN1878792A (zh) 2006-12-13
RU2006112849A (ru) 2007-12-20
TWI372060B (en) 2012-09-11
EP1668033A2 (fr) 2006-06-14
EP2423225A3 (fr) 2013-03-20
EP2248827A1 (fr) 2010-11-10
IL203007A0 (en) 2011-08-01
CO5680457A2 (es) 2006-09-29
IL203007A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
ATE473243T1 (de) Humane monoklonale antikörper gegen das kostimulatorische signaltransduktionsmolekül ailim und pharmazeutische verwendungen davon
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
EP1495055A4 (fr) Production d&#39;anticorps fonctionnels dans des champignons filamenteux
EP1567544A4 (fr) Utilisation de polypeptides hmgb permettant d&#39;accroitre des reponses immunitaires
EP1421933A4 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
EP1771188A4 (fr) Methodes et compositions destinees au traitement de l&#39;obesite, de maladies associees a l&#39;insuline et de l&#39;hypercholesterolemie
SE0102831D0 (sv) Anordning vid en handprotes
EP1942947A4 (fr) Polypeptides de fibronectine et methodes d&#39;utilisation
WO2003104986A8 (fr) Creation d&#39;interfaces utilisateurs au moyen de taches generiques
ATE410195T1 (de) Hydrokolloidzusammensetzungen
BRPI0510947A (pt) tratamento de doença respiratória
EP1422240A3 (fr) Analogues de la nociceptine
FR2865652B1 (fr) Utilisation d&#39;extraits de plantes et de molecules purifiees pour des compositions cosmetique, nutraceutique ou pharmaceutique a action amincissante lipolytique.
FR2915397B1 (fr) Composition pharmaceutique et/ou cosmetique contenant des principes actifs activateurs de l&#39;aconitase
PT1216007E (pt) Utilizacao de latex de borracha em combinacao com amido
ITRN20040042A1 (it) Garza chirurgica con matrice di identificazione
DK1694271T3 (da) FSH-glykosyleringsmutant
WO2002036050A1 (fr) Serre-poignet comportant un element roulant et coulissant
EP1677825A4 (fr) Peptide de liaison a une structure d&#39;anticorps anti-vih de neutralisation generale du complexe de fragment fab 4e 10, son utilisation et des compositions correspondantes
FR2859904B1 (fr) Perfectionnement aux dispositifs d&#39;osteosynthese de type vis, broche ou similaire
FR2894142B1 (fr) Utilisation de l&#39;association du dipeptide tyrosine-arginine et de la niacimanide en tant qu&#39;antagoniste de substance p
EP1845135A4 (fr) Composition contenant de l&#39;oxocarbone et son utilisation
EP1661911A4 (fr) Variante de l&#39;enterotoxine b du staphylocoque dore resistant aux proteases et vaccin en contenant
PT789761E (pt) Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica